XML 36 R25.htm IDEA: XBRL DOCUMENT v3.8.0.1

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Number of warrants excluded from weighted average common shares outstanding on a diluted basis.	3,675,000
Number of options excluded from weighted average common shares outstanding on a diluted basis.	5,750,500
Research and development cost	$ 210,624	$ 331,038
Helidyne LLC [Member]
Fair value of notes	$ (150,000)

X

- Definition

Number of options excluded from weighted average common shares outstanding on a diluted basis.

+ References

No definition available.

+ Details

Name:	pwvi_NumberOfOptionsExcludedFromWeightedAverageCommonSharesOutstandingOnADilutedBasis
Namespace Prefix:	pwvi_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Number of warrants excluded from weighted average common shares outstanding on a diluted basis.

+ References

No definition available.

+ Details

Name:	pwvi_NumberOfWarrantsExcludedFromWeightedAverageCommonSharesOutstandingOnADilutedBasis
Namespace Prefix:	pwvi_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 10
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=77997519&loc=d3e13433-108611

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=77997519&loc=d3e13476-108611

+ Details

Name:	us-gaap_DebtInstrumentFairValue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pwvi_HelidyneLLCMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: